POST MARKETING STUDY OF THE ELIXIR DESyne NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Novolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms EXCELLA PMCF
- Sponsors Elixir Medical Corporation
- 07 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
- 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.